Squamous cell carcinoma (SCC) of the breast is a rare malignancy that usually has a triple-negative phenotype and poor clinical outcomes. Because HER2-positive SCC of the breast is extremely rare, its clinicopathologic features are understudied, and the effects of neoadjuvant chemotherapy including anti-HER2-targeted therapy on the tumor are unclear, although treatment resistance was described in some reports. In this study, we reported a case of HER2-positive SCC of the breast in which a pathological complete response to neoadjuvant chemotherapy was observed.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613576 | PMC |
| http://dx.doi.org/10.1159/000519746 | DOI Listing |
Publication Analysis
Top Keywords
neoadjuvant chemotherapy
12
scc breast
12
pathological complete
8
complete response
8
response neoadjuvant
8
squamous cell
8
cell carcinoma
8
her2-positive scc
8
chemotherapy patient
4
patient her2-positive
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!